Table 1.

EGFR mutant lung cancer patients diagnosed at the University of Colorado Hospital and the University of California San Francisco were consented to an IRB-approved protocol to obtain tumor biopsies before and after 2 weeks of treatment with the indicated TKI.

Clinical characteristics of EGFR mutant lung cancer patients
Patient #	EGFR mutation	TP53	Co-mutations	EGFR TKI	Smoking status	Time to progression	Time on treatment
1	EGFR Exon19del	mut	PIK3CA	Osimertinib	Former	6.2 months	16 days
2	EGFR Exon19del	wt	PIK3CA	Erlotinib	Never	7 months	14 days
3	EGFR Exon19del	mut	RAF1	Osimertinib	Never	7 months	14 days
4	EGFR Exon19del	wt		Erlotinib	Never	8.6 months	10 days
5	EGFR-L858R	mut	N/A	Erlotinib	Never	13 months	14 days
6	EGFR Exon19del	wt		Erlotinib	Never	13.1 months	76 days
7	EGFR Exon19del	mut	APC	Osimertinib	Never	16 months	14 days
8	EGFR-L858R	mut	PIK3CA	Osimertinib	Never	16.3 months	24 days

The specific EGFR mutation, TP53 mutation status, notable co-mutations, smoking status, time to treatment progression, and time on treatment prior to rebiopsy.